• RESTRICT-seq Reveals KAT6A Dependency in SCC Resistance

  2026-06-03

  The reference study introduces RESTRICT-seq, a time-gated CRISPR screening approach, to map epigenetic dependencies underlying squamous cell carcinoma (SCC) resistance. Notably, the work identifies KAT6A as a critical epigenetic regulator of oncogene-induced senescence and resistance, providing actionable insights for targeted inhibition strategies.

• STING agonist-1: Accelerating STING Pathway Activation Workf

  2026-06-02

  STING agonist-1, a high-purity small molecule from APExBIO, empowers translational immunology by enabling reproducible, robust activation of the STING pathway in cancer and inflammation models. This article delivers actionable experimental workflows, protocol optimizations, and troubleshooting guidance, uniquely contextualized by recent breakthroughs in B cell-driven tertiary lymphoid structure biology.

• Neurotensin: Unlocking GPCR Trafficking and miRNA Research

  2026-06-02

  Neurotensin (CAS 39379-15-2) is redefining the landscape of translational research into G protein-coupled receptor (GPCR) trafficking and microRNA (miRNA) regulation, especially within gastrointestinal and central nervous system contexts. This thought-leadership article synthesizes mechanistic insights, strategic experimental guidance, and the latest advances in spectral analysis—offering a robust roadmap for researchers to deploy APExBIO Neurotensin with confidence. We connect mechanistic depth to workflow practicality, highlight the evolving competitive landscape, and forecast how interference-free, high-fidelity studies can accelerate translational breakthroughs.

• GI 254023X: Advanced Insights into Selective ADAM10 Inhibiti

  2026-06-01

  Explore how GI 254023X, a potent ADAM10 inhibitor, enables precise modulation of cellular signaling and vascular integrity, with unique mechanistic depth and application guidance. This article offers advanced insights for researchers seeking to leverage GI 254023X in translational models.

• SU5416 (Semaxanib): Advanced Protocols for Angiogenesis Inhi

  2026-06-01

  SU5416 (Semaxanib) empowers researchers to precisely modulate angiogenesis and immune signaling in cancer and vascular models. This guide details optimized workflows, advanced applications, and troubleshooting strategies that maximize SU5416's selectivity and reproducibility in translational research.

• ABT-263 (Navitoclax): Enhancing Apoptosis Assays in Cancer B

  2026-05-31

  ABT-263 (Navitoclax) is transforming apoptosis research with its potent, selective inhibition of Bcl-2 family proteins, enabling precise dissection of caspase-dependent cell death in oncology and senescence models. Explore protocol optimization, troubleshooting strategies, and the integration of skin-specific methylome analysis for age-related studies.

• Synthetic Lethality via WRN Loss and p53/PUMA in MSI Colon C

  2026-05-30

  This study uncovers the mechanistic basis of synthetic lethality between Werner helicase inhibition and mismatch repair deficiency in microsatellite instability (MSI) colorectal cancer. By demonstrating the dependence on p53 and PUMA-mediated apoptosis, the research highlights WRN as a promising target for p53-wildtype MSI CRCs, suggesting new avenues for therapeutic intervention.

• MK-1775 (Wee1 kinase inhibitor): Mechanisms, Efficacy & Use

  2026-05-29

  MK-1775 is a potent Wee1 kinase inhibitor with high selectivity and nanomolar potency. It disrupts the G2 DNA damage checkpoint, sensitizing p53-deficient tumor cells to DNA-damaging agents. This article details the mechanism, benchmarks, and workflow parameters, referencing peer-reviewed studies and product specifications.

• Applied Workflows with (-)-Norepinephrine (+)-bitartrate

  2026-05-29

  (-)-Norepinephrine (+)-bitartrate is the benchmark adrenergic receptor agonist for translational cardiovascular research, offering robust, reproducible induction of vasoconstrictive states and cardiomyopathy models. This article delivers stepwise experimental protocols, key insights from clinical data, and actionable troubleshooting to maximize assay reliability and outcome relevance.

• Reversine: Practical Protocols for Aurora Kinase Inhibition

  2026-05-28

  Reversine is a specialized small molecule Aurora kinase inhibitor for investigating mitotic regulation, cell cycle checkpoints, and cancer cell proliferation inhibition. It is optimized for in vitro and in vivo workflows targeting Aurora kinases A, B, and C, but should not be used for diagnostic or therapeutic applications.

• Eicosapentaenoic Acid (EPA): Mechanisms and Research Benchma

  2026-05-28

  Eicosapentaenoic Acid (EPA), a prominent EPA omega-3 fatty acid, is validated for its lipid-lowering and anti-inflammatory effects in cardiovascular disease research. Mechanistic studies confirm EPA's ability to modulate cell membrane composition and inhibit key cellular processes. This article delivers structured, evidence-based guidance for integrating high-purity EPA (SKU B3464) from APExBIO into laboratory workflows.

• D-Luciferin Potassium Salt: Optimizing In Vivo Imaging Workf

  2026-05-27

  D-Luciferin (potassium salt) unlocks high-sensitivity in vivo bioluminescence imaging with streamlined workflows and robust reproducibility. This guide translates bench research into actionable protocols and troubleshooting tips, empowering researchers to advance tumor cell tracking and luciferase reporter assays with confidence.

• GS-441524 Prodrug Innovation: Mechanistic Insights & Workflo

  2026-05-27

  Explore the scientific foundation and translational impact of GS-441524 prodrug research. This in-depth analysis reveals the mechanistic conversion pathways, advanced assay considerations, and practical implications for antiviral development.

• Niclosamide in Cancer Models: Beyond STAT3—Integrative Proto

  2026-05-26

  Explore how Niclosamide, a potent STAT3 signaling pathway inhibitor, enables robust cancer research workflows. This in-depth article uncovers integrated protocol guidance, novel insights from ATRX-deficient models, and practical assay considerations—providing unique value beyond standard reviews.

• Axitinib (AG 013736): Precision VEGF Inhibition in Cancer Re

  2026-05-26

  Axitinib (AG 013736) streamlines angiogenesis and tumor inhibition assays with unmatched selectivity and solubility, offering reproducible, quantifiable endpoints for cancer biology research. This guide details workflow enhancements, troubleshooting, and insights drawn directly from advanced in vitro drug response paradigms.

406 records 13/28 page Previous Next First page 上5页 1112131415 下5页 Last page